Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Basic Research in Cardiology
Erschienen in: Basic Research in Cardiology 3/2009

01.05.2009 | ORIGINAL CONTRIBUTION

Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats

verfasst von: Lei Yao, Guo-Ping Chen, Xian Lu, Liang-Rong Zheng, Yun Mou, Shen-Jiang Hu

Erschienen in: Basic Research in Cardiology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Previous clinical and experimental studies have demonstrated that statins, the inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, can improve left ventricular function in damaged hearts. Also, the normal expression of Ca2+ regulatory proteins is critical for efficient myocardial function. However, it is still unclear whether the beneficial effect of statins on cardiac function is associated with alterations of Ca2+ regulatory proteins. In this study, we investigated the effect of atorvastatin on cardiac function in spontaneously hypertensive rats (SHRs), focusing in particular on its impact on the expression of sarcoplasmic reticulum Ca2+-adenosine triphosphatase (SERCA2a), phospholamban (PLB) and its phosphorylated form (phosphorylated PLB), all of which are Ca2+ regulatory proteins in myocardium. SHRs showed decreases in gene expression of SERCA2a and phosphorylated PLB, and reduction in SERCA activity in the left ventricular myocardium, as well as reduced cardiac function, compared to age-matched Wistar Kyoto rats (WKYs). Furthermore, we showed that in SHRs atorvastatin preserved cardiac dysfunction accompanied by positive alterations in calcium regulatory proteins, with up-regulation in expression of SERCA2a and phosphorylated PLB, and with improvement of SERCA activity. Thus, atorvastatin has positive effects on calcium regulatory proteins, which may be one of the mechanisms of the beneficial effect of statins on cardiac function in spontaneously hypertensive rats.
Literatur
1.
Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic reticulum gene expression in human failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72:463–469PubMed
2.
Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H (2006) Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects. Cardiovasc Res 72:438–446PubMedCrossRef
3.
Black AE, Sinz MW, Hayes RN, Woolf TF (1998) Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylgutaryl-coa reductase inhibitor atorvastatin. Drug Metab Dispos 26:755–763PubMed
4.
Boknik P, Heinroth-Hoffmann I, Kirchhefer U, Knapp J, Linck B, Luss H, Muller T, Schmitz W, Brodde O, Neumann J (2001) Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovasc Res 51:717–728PubMedCrossRef
5.
Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD (2004) PKC-α regulates cardiac contractility and propensity toward heart failure. Nat Med 10:248–254PubMedCrossRef
6.
Carr AN, Schmidt AG, Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB, Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA, Kranias EG (2002) Type 1 phosphatase, a negative regulator of cardiac function. Moll Cell Biol 22:4124–4135CrossRef
7.
Collins HL, Loka AM, Dicarlo SE (2004) Daily exercise-induced cardioprotection is associated with changes in calcium regulatory proteins in hypertensive rats. Am J Physiol Heart Circ Physiol 288:532–540CrossRef
8.
Del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK, Lewandowski ED, Hajjar RJ (2001) Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104:1424–1429PubMedCrossRef
9.
Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN (2003) Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285:H2373–H2381PubMed
10.
Haghighi K, Gregory KN, Kranias EG (2004) Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322:1214–1222PubMedCrossRef
11.
Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, Kemp BE, Venema RC (2004) Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287:H560–H566PubMedCrossRef
12.
Hasenfuss G, Pieske B (2002) Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34:951–969PubMedCrossRef
13.
Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A (2002) Fluvastatin, a 3-Hydroxy-3-Methylglutaryl coenzyme A reductase inhibitor, attenuate left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868–873PubMedCrossRef
14.
Jones LR, Besch HR, Fleming JW, McConnaughey MM, Watanabe AM (1979) Separation of vesicles of cardiac sarcolemma from vesicles of cardiac sarcoplasmic reticulum. Comparative biochemical analysis of component activities. J Biol Chem 254:530–539PubMed
15.
Kokubo M, Uemura A, Matsubara T, Murohara T (2005) Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. Hypertens Res 28:601–609PubMedCrossRef
16.
Kubo H, Margulies KB, Piacentino V, Gaughan JP, Houser SR (2001) Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104:1012–1018PubMedCrossRef
17.
Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, Shinozuka K (2006) Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 29:1756–1758PubMedCrossRef
18.
Lamberts RR, Vaessen RJ, Westerhof N, Stienen GJ (2007) Right ventricular hypertrophy causes impairment of left ventricular diastolic function in the rat. Basic Res Cardiol 102(1):19–27PubMedCrossRef
19.
Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, Drexler H (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110:1933–1939PubMedCrossRef
20.
Maack C, O’Rourke B (2007) Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol 102(5):369–392PubMedCrossRef
21.
Maier LS, Wahl-Schott C, Horn W, Weichert S, Pagel C, Wagner S, Dybkova N, Müller OJ, Nabauer M, Franz WM, Pieske B (2005) Increased SR Ca2+ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats. Cardiovasc Res 67:636–646PubMedCrossRef
22.
Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92:778–784PubMed
23.
Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR (1999). Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99:313–322PubMedCrossRef
24.
Mousa SA, Goncharuk O, Miller D (2007) Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin Biol Ther 7:617–625PubMedCrossRef
25.
Nef HM, Mollmann H, Skwara W, Bolck B, Schwinger RH, Hamm Ch, Kostin S, Schaper J, Elsasser A (2006) Reduced sarcoplasmic reticulum Ca2+-ATPase activity and dephosphorylated phospholamban contribute to contractile dysfunction in human hibernating myocardium. Mol Cell Biochem 282:53–63PubMedCrossRef
26.
Node K, Fujita M, Kitakaze M, Hori M, Liao JK (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108:839–843PubMedCrossRef
27.
Porter MJ, Heidkamp MC, Scully BT, Patel N, Martin JL, Samarel AM (2003) Isoenzyme-selective regulation of SERCA2 gene expression by protein kinase C in neonatal rat ventricular myocytes. Am J Physiol Cell Physiol 285:C39–C47PubMed
28.
Rejane P, Christophe B, Olicier B et al (2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res 98:361–369CrossRef
29.
Renna BF, Kubo H, MacDonnell SM, Crabbe DL, Reger PO, Houser SR, Libonati JR (2006) Enhanced acidotic myocardial Ca2+ responsiveness with training in hypertension. Med Sci Sport Exer 38:847–855CrossRef
30.
Sande JB, Sjaastad I, Hoen IB, Bøkenes J, Tønnessen T, Holt E, Lunde PK, Christensen G (2002) Reduced level of serine (16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 53:382–391PubMedCrossRef
31.
Sevilla MA, Voces F, Carrón R, Guerrero EI, Ardanaz N, San Román L, Arévalo MA, Montero MJ (2004) Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. Life Sci 75:881–891PubMedCrossRef
32.
Simko F, Matuskova J, Luptak I, Krajcirovicova K, Kucharska J, Gvozdjakova A, Babal P, Pechanova O (2004) Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 74:1211–1214PubMedCrossRef
33.
Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332–337PubMedCrossRef
34.
Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY (2005) Effect of β-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128:1812–1821PubMedCrossRef
35.
Tanaka K, Honda M, Takabatake T (2004) Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 31:360–364PubMedCrossRef
36.
Weber T, Neumann J, Meissner A, Grosse Hartlage M, Van Aken H, Schmitz W, Boknik P (2006) Reduced serine-16 and threonine-17 phospholamban phosphorylation in stunning of conscious dogs: no evidenced for any involvement of protein kinase A or protein phosphatases. Basic Res Cardiol 101:253–260PubMedCrossRef
37.
Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Poloński L, Dyrbus K, Badziński A, Mercik G, Zembala M, Wodniecki J, Rozek MM (2006) Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97:899–904PubMedCrossRef
38.
Yasunari K, Maeda K, Minami M, Yoshikawa J (2001) HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 21:937–942PubMed
39.
Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, Ohtani T, Miwa T, Hori M, Masuyama T (2004) AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 43:686–691PubMedCrossRef
40.
Zheng X, Hu SJ (2005) Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 26:696–704PubMedCrossRef
Metadaten
Titel
Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats
verfasst von
Lei Yao
Guo-Ping Chen
Xian Lu
Liang-Rong Zheng
Yun Mou
Shen-Jiang Hu
Publikationsdatum
01.05.2009
Erschienen in
Basic Research in Cardiology / Ausgabe 3/2009
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-008-0751-y

Weitere Artikel der Ausgabe 3/2009

Basic Research in Cardiology 3/2009 Zur Ausgabe

ORIGINAL CONTRIBUTION

Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue factor and arterial thrombosis

ORIGINAL CONTRIBUTION

Modulation of L-type Ca2+ channel current density and inactivation by β-adrenergic stimulation during murine cardiac embryogenesis

ORIGINAL CONTRIBUTION

Aging-associated insulin resistance predisposes to hypertension and its reversal by exercise: the role of vascular vasorelaxation to insulin

ORIGINAL CONTRIBUTION

Role of the Innate Immune System in Acute Viral Myocarditis

ORIGINAL CONTRIBUTION

The effect of enhanced gap junctional conductance on ventricular conduction in explanted hearts from patients with heart failure

INVITED REVIEW

Vascular control in humans: focus on the coronary microcirculation

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise